Julie Kanter, Kenneth I Ataga, Neha Bhasin, Stephanie Guarino, Abdullah Kutlar, Sophie Lanzkron, Deepa Manwani, Patrick McGann, Sean R Stowell, Venée N Tubman, Irina Yermilov, Cynthia Campos, Michael S Broder
Crizanlizumab, a monoclonal antibody against P-selectin, has been shown to reduce vaso-occlusive crises (VOCs) compared to placebo in patients ≥ 16 years with sickle cell disease (SCD). However, there have been rare reports of patients experiencing severe pain and subsequent complications within 24 hours of crizanlizumab infusions. These events are defined as infusion-related reactions (IRRs). Informed by current literature and clinical experience, a group of content experts developed clinical guidelines for the management of IRRs in patients with SCD...
April 20, 2024: Annals of Hematology